The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Advances Changing the Treatment Landscape of AML

Kamal Menghrajani, MD
Published Online:1:49 PM, Wed September 12, 2018


Kamal Menghrajani, MD, a hematologist/oncologist at Memorial Sloan Kettering Cancer Center, discusses the latest advancement in the research of acute myeloid leukemia (AML). After treating this disease the same way with traditional chemotherapy for over 40 years, researchers have finally come to an understanding of what is happening in the AML cells, leading to a more precise treatment of these patients.

While there has been little to no advance in the treatment landscape for several decades, understanding what happens in AML cells as they develop has helped advance the field in a number of ways, Menghrajani says. The first major advance includes CPX-351 (Vyxeos), a combination of 2 different chemotherapies. By combining these traditional chemotherapies, the new formula can target AML better than either of the 2 agents could alone. 

Menghrajani also says that IDH inhibitors are changing the field. IDH inhibitors, either IDH1 or IDH2, can target that specific cell. Menghrajani adds that having this oral pill available for patients with AML has really changed the field.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.